These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 34034278)

  • 61. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis.
    Reinisch W; Sandborn WJ; Bala M; Yan S; Feagan BG; Rutgeerts P; Radford-Smith G; Xu S; Eisenberg D; Olson A; Colombel JF
    Inflamm Bowel Dis; 2007 Sep; 13(9):1135-40. PubMed ID: 17476675
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis.
    Rutgeerts P; Feagan BG; Marano CW; Padgett L; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Zhang H; Colombel JF; Reinisch W; Gibson PR; Sandborn WJ;
    Aliment Pharmacol Ther; 2015 Sep; 42(5):504-14. PubMed ID: 26119226
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Subcutaneously Administered Anti-TNFs for the Treatment of Ulcerative Colitis: A Retrospective, Propensity Score-Matched, US Health Claims Analysis.
    Stewart MJ; Bessissow T; Gregor J; Hazel M; In TSH; Karra K; Dajnowiec D; Williamson M; Sattin B
    Adv Ther; 2021 Jul; 38(7):4115-4129. PubMed ID: 34159558
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis.
    Renna S; Mocciaro F; Ventimiglia M; Orlando R; Macaluso FS; Cappello M; Fries W; Mendolaro M; Privitera AC; Ferracane C; Pisana V; Magnano A; Pluchino D; Inserra G; Scarpulla G; Garufi S; Carroccio A; Siringo S; Di Mitri R; Cottone M; Orlando A
    Dig Liver Dis; 2018 Dec; 50(12):1292-1298. PubMed ID: 30007516
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort.
    Bossuyt P; Baert F; D'Heygere F; Nakad A; Reenaers C; Fontaine F; Franchimont D; Dewit O; Van Hootegem P; Vanden Branden S; Lambrecht G; Ferrante M;
    Inflamm Bowel Dis; 2019 Jan; 25(1):156-162. PubMed ID: 29920582
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label.
    Stefanovic S; Detrez I; Compernolle G; Brouwers E; Sever N; Stabuc B; Smrekar N; Kurent T; Novak G; Kozelj M; Ferrante M; Gils A; Drobne D
    Eur J Gastroenterol Hepatol; 2021 Jan; 33(1):54-61. PubMed ID: 32804854
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study.
    Samaan MA; Cunningham G; Tamilarasan AG; Beltran L; Pavlidis P; Ray S; Mawdsley J; Anderson SH; Sanderson JD; Arkir Z; Irving PM
    Aliment Pharmacol Ther; 2020 Jul; 52(2):292-302. PubMed ID: 32506695
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A Systematic Review of the Economic and Health-Related Quality of Life Impact of Advanced Therapies Used to Treat Moderate-to-Severe Ulcerative Colitis.
    Cichewicz A; Tencer T; Gupte-Singh K; Egodage S; Burnett H; Kumar J
    Adv Ther; 2023 May; 40(5):2116-2146. PubMed ID: 37000363
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Patient Education in a 14-month Randomised Trial Fails to Improve Adherence in Ulcerative Colitis: Influence of Demographic and Clinical Parameters on Non-adherence.
    Nikolaus S; Schreiber S; Siegmund B; Bokemeyer B; Bästlein E; Bachmann O; Görlich D; Hofmann U; Schwab M; Kruis W
    J Crohns Colitis; 2017 Sep; 11(9):1052-1062. PubMed ID: 28486634
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece.
    Vellopoulou K; Stefanou G; Tzanetakos C; Boubouchairopoulou N; Nakou M; Gourzoulidis G; Kourlaba G
    Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):325-333. PubMed ID: 32976189
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohort.
    Claudepierre P; Van den Bosch F; Sarzi-Puttini P; Vastesaeger N; Govoni M; Kachroo S
    Int J Rheum Dis; 2019 Jun; 22(6):995-1001. PubMed ID: 30989813
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
    Panés J; Su C; Bushmakin AG; Cappelleri JC; Mamolo C; Healey P
    BMC Gastroenterol; 2015 Feb; 15():14. PubMed ID: 25651782
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Golimumab for the treatment of ulcerative colitis.
    Flamant M; Paul S; Roblin X
    Expert Opin Biol Ther; 2017 Jul; 17(7):879-886. PubMed ID: 28472597
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The relationship among multiple patient-reported outcomes measures for patients with ulcerative colitis receiving treatment with MMX ® formulated delayed-release mesalamine.
    Yarlas A; Yen L; Hodgkins P
    Qual Life Res; 2015 Mar; 24(3):671-83. PubMed ID: 25193617
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Unmet Needs in Real-World Advanced Therapy-Naïve and -Experienced Patients with Moderately to Severely Active Ulcerative Colitis in the United States.
    Afzali A; Lukanova R; Hennessy F; Kakehi S; Knight H; Milligan G; Gupte-Singh K
    Adv Ther; 2023 Oct; 40(10):4321-4338. PubMed ID: 37458875
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Restoration of quality of life of patients with inflammatory bowel disease after one year with antiTNFα treatment.
    Casellas F; Robles V; Borruel N; Torrejón A; Castells I; Navarro E; Guarner F
    J Crohns Colitis; 2012 Oct; 6(9):881-6. PubMed ID: 22398074
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
    Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
    Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
    Burisch J
    Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study.
    Viola A; Pugliese D; Renna S; Furfaro F; Caprioli F; D'Incà R; Bossa F; Mazza S; Costantino G; Fantini MC; Fiorino G; Alibrandi A; Orlando A; Armuzzi A; Fries W
    Dig Liver Dis; 2019 Apr; 51(4):510-515. PubMed ID: 30472389
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice.
    Marutani Y; Mizoshita T; Sugiyama T; Togawa S; Katano T; Yamada T; Hirata Y; Kimura Y; Miyaki T; Inoue Y; Suzuki E; Sasaki M; Kataoka H
    Indian J Gastroenterol; 2020 Dec; 39(6):565-575. PubMed ID: 33106991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.